Meningokok Aşıları

Abstract

Neisseria meningitidis, asemptomatik taşıyıcılıktan yaşamı tehdit eden invazif meningokok hastalığına kadar geniş bir yelpazede karşımıza çıkmaktadır. Hastalığa karşı,dünyada yaygın olarak kullanımda olan iki çeşit polisakkarit ve konjüge meningokok aşısı mevcuttur. Polisakkarit meningokok aşıları 2 yaşından sonra, özellikle invazif meningokok hastalık riskinin arttığı adolesan ve genç erişkinlerde, konjüge aşıların bulunmadığı ülkelerde tercih edilmektedir. Konjüge meningokok aşılarından MenACWYCRM, 2 aylıktan itibaren kullanılabilmesi nedeniyle önem taşımaktadır. Yapılan çalışmalar sonucu MenACWY-CRM aşısı sütçocuğu, çocuk, adolesan ve erişkinlerde etkin ve düşük yan etki profiline sahip bulunmuştur

Keywords

• İnvaziv meningokok hastalığı, meningokok aşıları, MenACWY-CRM aşısı

Meningococcal Vaccines

Abstract

Neisseria meningitidis confronts us in a wide spectrum of diseases ranging from asymptomatic carriership to life-threatening invasive meningococcal disease. Worldwide, two types of meningococcal vaccines polysaccharide and conjugated are in clinical use against the disease. Polysaccharide meningococcal vaccines are preferred in countries where there is no access of conjugate vaccine in adolescents and young adults after the age of 2, who are particularly at risk for invasive meningococcal disease. As one of the conjugated meningococcal vaccines MenACWY-CRM is important since it can be used from 2 months of age. The results of the studies have shown that the MenACWY-CRM vaccine is effective and has a low side-effect profile in infants, children, adolescents and adults.

Keywords

• Invasive meningococcal disease, meningococcal vaccines, MenACWY-CRM vaccine

References

1. 1. Aslan N, Özen M. Meningokok tarihçesi. In: Kara A, Çiftçi E, Tezer H, eds. Çocukluk Çağında Meningokok Hastalıkları, 1st ed. İstanbul: Selen Yayıncılık, 2016: 9-15.
2. 2. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Meth Mol Biol. 2012;799:1-20. https://doi.org/10.1007/978-1-61779-346-2_1
3. 3. T.C. Başbakanlık Türkiye İstatistik Kurumu Ölüm İstatistikleri. Ölüm nedenlerinin cinsiyete göre dağılımı, 27/04/2017 tarihi itibariyle, 2009-2016. http://www.tuik.gov.tr/PreTablo.do?alt_id=1083.
4. 4. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:273.
5. 5. Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2013;62 (RR02):1-22.
6. 6. Croxtall JD, Dhillon S. Meningococcal quadrivalent (serogroups A, C, W-135 and Y) tetanus toxoid conjugate vaccine (Nimenrix). Drugs 2012;72: 2407-30. https://doi.org/10.2165/11209580-000000000-00000
7. 7. Miller JM, Mesaros N, Van Der Wielen M, Baine Y. Conjugate meningococcal vaccines development: GSK Biologicals Experience. Adv Preventive Med 2011;2011:846756. https://doi.org/10.4061/2011/846756
8. 8. Karaaslan A, Soysal A. Meningokok polisakkarid aşılar. In: Kara A, Çiftçi E, Tezer H, eds. Çocukluk Çağında Meningokok Hastalıkları, 1st ed. İstanbul: Selen Yayıncılık, 2016: 171-75.

9. 9. Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACW-TT, NimenrixTM): A review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother 2016;12:1825-37. https://doi.org/10.1080/21645515.2016.1143157
10. 10. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, et al. Safety, immunogenecity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007;25:101-7. https://doi.org/10.1016/j.vaccine.2007.04.050
11. 11. Belet N. Konjuge meningokok C aşısı ve Avrupa deneyimi. In: Kara A, Çiftçi E, Tezer H, eds. Çocukluk Çağında Meningokok Hastalıkları, 1st ed. İstanbul: Selen Yayıncılık, 2016:181-91.
12. 12. Centers for Disease Control and Prevention (CDC). Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-- United States, June-July 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1023-25.
13. 13. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR Morb Mortal Wkly Rep. 2006;55:1120-4.
14. 14. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1018-9.
15. 15.GlaxoSmithKline Inc. Nimenrix_Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine. Product Monograph GlaxoSmithKline Inc 2015.
16. 16. Dbaibo G, Macalalad N, Reyes MRA-DL, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. Hum Vaccin Immunother 2012;8:873-80. https://doi.org/10.4161/hv.20211
17. 17.Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial. Drugs Aging 2013;30:309-19. https://doi.org/10.1007/s40266-013-0065-0
18. 18. Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr Infect Dis J. 2011;30:e41-8. https://doi.org/10.1097/INF.0b013e3182054ab9
19. 19.Güneş C, Tezer H. MenACWY-TT aşısı (Nimenrix). In: Kara A, Çiftçi E, Tezer H, eds. Çocukluk Çağında Meningokok Hastalıkları, 1st ed. İstanbul: Selen Yayıncılık, 2016:209-11.
20. 20.Novartis media release. FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age. http://www.novartisvaccines. com/newsroom/mediareleases/2013/US_ Menveo_Infant_FDA_Approval_Press_Release_ US.pdf.
21. 21. https://www.titck.saglik.gov.tr/PortalAdmin/ Uploads/KubKT/pvOTDze9TtfSal.pdf
22. 22. MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63: 527.
23. 23. Food and Drug Administration. Product approval information: package insert. Menveo (Meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). http://www.fda.go v/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ ucm201349.pdf (Accessed on:10.06.2015).
24. 24. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010;28:744-53. https://doi.org/10.1016/j.vaccine.2009.10.064
25. 25. Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J 2013;760-67. https://doi.org/10.1097/INF.0b013e31828693c5
26. 26. Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vacc Immunotherapeutics 2012;8:1892-903. https://doi.org/10.4161/hv.22166
27. 27.Ostergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009; 27: 161-68. https://doi.org/10.1016/j.vaccine.2008.08.075
28. 28. Somer A. Meningokok B aşıları. In: Kara A, Çiftçi E, Tezer H, eds. Çocukluk Çağında Meningokok Hastalıkları, 1st ed. İstanbul: Selen Yayıncılık, 2016: 213-24.
29. 29.Dull PM, McIntosh ED. Meningococcal vaccine development-- from glycoconjugates against MenACWY to proteins against MenB-potential for broad protection against meningococcal disease. Vaccine 2012;30 (Suppl 2):18-25. https://doi.org/10.1016/j.vaccine.2012.01.062
30. 30. https://gsksource.com/pharma/content/dam/ GlaxoSmithKline/US/en/Prescribing_Information /Bexsero/pdf/BEXSERO.PDF
31. 31. Kim DK, Riley LE, Harriman KH. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med. 2017;166:209. https://doi.org/10.7326/M16-2936
32. 32. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816. https://doi.org/10.1126/science.287.5459.1816
33. 33.Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103(29): 10834-9. https://doi.org/10.1073/pnas.0603940103
34. 34. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195(11):1445-54. https://doi.org/10.1084/jem.20020407
35. 35. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416-25. https://doi.org/10.1016/S1473-3099(13)70006-9
36. 36. Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER. The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012;30:B67-72. https://doi.org/10.1016/j.vaccine.2011.12.126
37. 37. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013;32:1116-21. https://doi.org/10.1097/INF.0b013e31829cfff2
38. 38. Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013;32:124-30. https://doi.org/10.1016/j.vaccine.2013.03.063
39. 39. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35. https://doi.org/10.1016/S0140-6736(12)61961-8
40. 40. Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebocontrolled study. Lancet 2012;379:617-24. https://doi.org/10.1016/S0140-6736(11)61713-3
41. 41.Haut Conseil de la Sante’ Publique. Vaccination contre les infections invasives a’ meningocoque B, place du vaccin Bexsero1. Available from: URL: http:// www.hcsp.fr/explore.cgi/avisrapportsdomaine? clefr=386. [French], 2013.
42. 42. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27:B112-6. https://doi.org/10.1016/j.vaccine.2009.04.065
43. 43. Marshall H, Clarke M, Sullivan T. Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines. Vaccine 2014;32:338-44. https://doi.org/10.1016/j.vaccine.2013.11.042
44. 44. Kaaijk P, van der Ende A, Luytjes W. Routine vaccination against MenB: considerations for implementation. Hum Vaccin Immunother 2013;10:310-6. https://doi.org/10.4161/hv.26816
45. 45. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82. https://doi.org/10.1001/jama.2012.85
46. 46. Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB- FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509. https://doi.org/10.15585/mmwr.mm6619a6
47. 47. Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608. https://doi.org/10.15585/mmwr.mm6441a3